Key result
Almokalant infusion induced torsades de pointes in 6% of patients with atrial fibrillation or flutter, with baseline T wave alternans (50% vs 4%, P<0.01) acting as a significant predictor.
Why the study?
What are the clinical and electrocardiographic predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter?
Population
100 patients with chronic atrial fibrillation or flutter
Design
Cohort
Follow-up
2 days (infusion 1 and infusion 2 on the following day)
Authors
Loading...
T-wave alternans during AF may flag TdP risk on almokalant; hypothesis-generating and requires prospective validation before guiding use.
Cohort (n=100)
What are the clinical and electrocardiographic predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter?
Early pronounced QT prolongation, increased QT dispersion, and morphological T wave changes, along with female gender and diuretic use, predict almokalant-induced torsades de pointes in AF patients.
Houltz et al. (1998) conducted a cohort in chronic atrial fibrillation or flutter (n=100). almokalant infusion was evaluated on torsades de pointes (TdP). Almokalant infusion induced torsades de pointes in 6% of patients with atrial fibrillation or flutter, with baseline T wave alternans (50% vs 4%, P<0.01) acting as a significant predictor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: